Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $9.6 million.

  • Beam Therapeutics' Gains from Investment Securities fell 109.96% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year decrease of 4.75%. This contributed to the annual value of $9.6 million for FY2024, which is 16.06% up from last year.
  • According to the latest figures from FY2024, Beam Therapeutics' Gains from Investment Securities is $9.6 million, which was up 16.06% from $8.3 million recorded in FY2023.
  • Beam Therapeutics' Gains from Investment Securities' 5-year high stood at $9.6 million during FY2024, with a 5-year trough of $5.3 million in FY2020.
  • In the last 3 years, Beam Therapeutics' Gains from Investment Securities had a median value of $8.3 million in 2023 and averaged $8.5 million.
  • Data for Beam Therapeutics' Gains from Investment Securities shows a peak YoY increased of 25.09% (in 2022) over the last 5 years.
  • Over the past 5 years, Beam Therapeutics' Gains from Investment Securities (Yearly) stood at $5.3 million in 2020, then climbed by 13.08% to $6.0 million in 2021, then climbed by 25.09% to $7.5 million in 2022, then climbed by 9.64% to $8.3 million in 2023, then rose by 16.06% to $9.6 million in 2024.